4-Methyloctahydro-1H-pyrrolo[3,2-b]pyridine | 1369343-83-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-Methyloctahydro-1H-pyrrolo[3,2-b]pyridine
• 英文别名: 4-methyl-1,2,3,3a,5,6,7,7a-octahydropyrrolo[3,2-b]pyridine
• CAS: 1369343-83-8
• 化学式: C₈H₁₆N₂
• 分子量: 140.23
• InChiKey: UVIBURNTGPPPMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] BICYCLIC INHIBITORS OF PAD4<br/>[FR] INHIBITEURS BICYCLIQUES DE PAD4
  申请人：PADLOCK THERAPEUTICS INC

  公开号：WO2017100594A1

  公开（公告）日：2017-06-15

  The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

  本发明提供了用作PAD4抑制剂的化合物、其组合物以及治疗与PAD4相关疾病的方法。
• [EN] MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT<br/>[FR] INHIBITEURS MACROCYCLIQUES DE PAD4 UTILES EN TANT QU'IMMUNOSUPPRESSEURS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021158840A1

  公开（公告）日：2021-08-12

  The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, (I) wherein ring A, A1, A2, A3, A4, Q, R1, R2, R3, R4, R5, and R6 along with other variables are as defined herein.

  本发明提供了一种化合物，其化学式为（I），用作PAD4的抑制剂，以及其组合物和治疗PAD4相关疾病的方法，其中环A，A1，A2，A3，A4，Q，R1，R2，R3，R4，R5和R6以及其他变量如本文所定义。
• [EN] ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR<br/>[FR] ANTAGONISTES DU RÉCEPTEUR A2A DE L'ADÉNOSINE
  申请人：ADORX THERAPEUTICS LTD

  公开号：WO2021224636A1

  公开（公告）日：2021-11-11

  The present invention relates to compounds of formula I shown below: wherein R0, R1, R2, R3 and A are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a receptor activity is implicated, such as, for example, cancer.

  本发明涉及如下所示的公式I的化合物：其中R0、R1、R2、R3和A分别如申请中所定义。本发明还涉及制备这些化合物的方法，包括它们的药物组合物，并将其用于治疗涉及腺苷A2a受体活性的疾病或症状，例如癌症。
• QUINOLINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO THE MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR
  申请人：Abbvie Deutschland GmbH & Co. KG

  公开号：US20170260158A1

  公开（公告）日：2017-09-14

  The present invention relates to quinoline compounds of formula I wherein the variables are defined as in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators of the 5-HT 6 receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of the 5-HT 6 receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of the 5-HT 6 receptor.

  本发明涉及公式I的喹啉化合物，其中变量的定义如索引和描述中所述。本发明还涉及含有这种化合物的药物组合物，以及它们作为5-HT6受体调节剂的用途，用于制备用于预防或治疗对5-HT6受体调节有反应的疾病和疾病的药物，以及用于预防或治疗对5-HT6受体调节有反应的疾病和疾病的方法。
• Cinnamide Compound
  申请人：Kimura Teiji

  公开号：US20080070902A1

  公开（公告）日：2008-03-20

  The present invention relates to a compound represented by Formula (I): (wherein Ar 1 represents an imidazolyl group which may be substituted with 1 to 3 substituents; Ar 2 represents a pyridinyl group, a pyrimidinyl group, or a phenyl group which may be substituted with 1 to 3 substituents; X 1 represents (1) —C≡C— or (2) a double bond etc. which may be substituted; R 1 and R 2 represent, for example, a C1-6 alkyl group or C3-8 cycloalkyl group which may be substituted) or a pharmacologically acceptable salt thereof and to the use thereof as pharmaceutical agents.

  本发明涉及一种由公式(I)表示的化合物：（其中Ar1代表一个咪唑基，可以用1到3个取代基取代；Ar2代表一个吡啶基，嘧啶基或苯基，可以用1到3个取代基取代；X1代表（1）-C≡C-或（2）一个双键等，可以用取代基取代；R1和R2代表例如C1-6烷基或C3-8环烷基，可以用取代基取代）或其药学上可接受的盐，并用作制药剂。